About Us

Our goal is to provide proof-of-concept that our antibody directed therapeutics targeting SAS1B can ablate human cancer cells in animal models with little or no toxic effects on healthy cells. After proof-of-concept, we anticipate partnering with leading pharmaceutical/biotechnology companies to advance our candidate targeted cancer therapeutics. If successful with targeting the SAS1B neoantigen, we will move additional oocyte-associated cancer proteins into our discovery pipeline.

In addition to partnering with pharma companies to develop antibody-drug conjugate therapeutics, we are actively working with research leaders in the emerging immunotherapy space who are developing cell-based cancer immunotherapies, utilizing technologies such as chimeric antigen receptors (CARs), to target cellular immunity to attack tumor cells with the same degree of specificity.